Feng Shen

TL;DR: The NDR scoring system was more accurate in selecting patients with multiple HCCs for hepatectomy and was also larger than the four conventional staging systems.

TL;DR: In this article, a review aimed to summarize recent advances in utilizing molecular biomarkers in hepatocellular carcinoma (HCC) and discuss their clinical significance, as well as identifying more promising candidate biomarkers and therapeutic targets for diagnosis, treatment, and monitoring responses of HCC to conventional therapies.

TL;DR: The proposed scoring system provides an effective tool for selecting the patients most likely to benefit from adjuvant chemolipiodolization after liver resection for hepatocellular carcinoma (HCC) and optimally stratified patients into three prognostic subgroups with scores of 0–5, 6–9 and ≥ 10, having better, medium and worse survival outcomes, respectively.

TL;DR: Patients with known risk factors for recurrence had even more marked improvements in cDFS3 over subsequent years versus patients without risk factorsfor recurrence, while actuarial DFS following liver resection increased over time.